Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heron hammered over Sustol NDA resubmission delay

This article was originally published in Scrip

Executive Summary

Investors hammered Heron Therapeutics on 27 January, with shares tumbling as low as 19.2% in morning trading, after the company revealed it was forced to delay by at least three months its resubmission to the FDA of the firm’s new drug application (NDA) for its experimental chemotherapy-induced nausea and vomiting (CINV) drug Sustol (APF530).

You may also be interested in...

Heron's Sustol Faces Competition With Narrower Label Than Expected

Heron Therapeutics gained approval of its chemotherapy-induced nausea and vomiting drug Sustol (granisetron), but the company faces stiff competition and postmarketing requirements. Analysts, nonetheless, think the product has a bright future on the US market.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Allergan's Price Reform Pledge: Will Others Follow?

Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts